共 94 条
[1]
Llovet JM(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[2]
Ricci S(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[3]
Mazzaferro V(2018)Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Hepatology 68 723-750
[4]
Bray F(2010)Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 v59-v64
[5]
Ferlay J(2018)EASL Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol 69 182-236
[6]
Soerjomataram I(1999)Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 329-338
[7]
Siegel RL(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34
[8]
Torre LA(2006)Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature Methods Enzymol 407 597-612
[9]
Jemal A(2016)Cancer and liver cirrhosis: implications on prognosis and management ESMO Open 1 e000042-511
[10]
Marrero JA(2010)Magnetic resonance elastography: a review Clin Anat 23 497-247